Clinical Trial Update: The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers [Phase 2]

View source ↗

Summary

Phase 2 trial update on long-term antibody persistence of GSK134612 meningococcal vaccine in healthy toddlers; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• GSK134612 (Meningococcal vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 2 | Status: COMPLETED | Results posted: 2018-08-23